Kwangdong Pharmaceutical · 연결재무제표기준영업(잠정)실적(공정공시)
Preliminary consolidated operating results (Fair Disclosure)
| Results Period | |||
| Current Period Results | 2026-07-01 | ~ | 2026-09-30 |
| Prior Period Results | 2026-04-01 | ~ | 2026-06-30 |
| Prior-Year Same Period Results | 2025-07-01 | ~ | 2025-09-30 |
| Current Period Cumulative Results | 2026-01-01 | ~ | 2026-09-30 |
| Prior-Year Same Period Cumulative Results | 2025-01-01 | ~ | 2025-09-30 |
| ※ Preliminary figures; subject to change upon finalization. | ||||||||
| 1. Consolidated results | Unit: KRW m, % | |||||||
| Category | Current Period Results | Prior Period Results | vs. Prior Period | Prior-Year Same Period Results | YoY | |||
| (2026.3Q) | (2026.2Q) | Change (%) | Profit/loss turnaround | (2025.3Q) | Change (%) | Profit/loss turnaround | ||
| Revenue | Current Results | 460,613 | 439,816 | 4.7 | - | 444,517 | 3.6 | - |
| Cumulative Results | 1,311,283 | - | - | - | 1,247,410 | 5.1 | - | |
| Operating Income | Current Results | 7,039 | 2,823 | 149.4 | - | 10,869 | -35.2 | - |
| Cumulative Results | 17,383 | - | - | - | 18,718 | -7.1 | - | |
| Income from continuing operations before income tax | Current Results | 785 | 4,442 | -82.3 | - | 14,320 | -94.5 | - |
| Cumulative Results | 11,786 | - | - | - | 23,397 | -49.6 | - | |
| Net Income | Current Results | 657 | 3,164 | -79.2 | - | 11,106 | -94.1 | - |
| Cumulative Results | 8,721 | - | - | - | 17,563 | -50.3 | - | |
| Net income attributable to owners of the parent | Current Results | 1,153 | 2,708 | -57.4 | - | 10,787 | -89.3 | - |
| Cumulative Results | 8,262 | - | - | - | 17,042 | -51.5 | - | |
| - | - | - | - | - | - | - | - | |
| 2. Information Provided | Information Provider | 광동제약(주) 자금팀 | ||||||
| Information Recipient | 국내외 정보이용자 | |||||||
| Information release date (scheduled) | Ad Hoc Provision After Fair Disclosure | |||||||
| Information release time (scheduled) | - | |||||||
| Event Name (Venue) | - | |||||||
| 3. Contact | Responsible Department | 광동제약(주) 자금팀 | ||||||
| Phone Number | 02-6006-7734 | |||||||
| 4. Other Material Matters Relevant to Investment Decisions | ||||||||
| - 상기 내용은 한국채택국제회계기준(K-IFRS)에 따라 작성된 연결기준 잠정영업실적입니다. - 상기 실적은 외부감사인의 검토가 완료되지 않은 자료로, 향후 검토 결과에 따라 변경될 수 있습니다. | ||||||||
| ※ Related Disclosures | 2026-10-30 Advance Notice of Annual Results Disclosure (Guidance Disclosure) | |||||||